bioRxiv· Greenall, S. A., Chen, S. C., Alton, G., Beaton, G., Boelter, R., Casey, M., Babic, I., Bruce, Z. C., Garama, D. J., Mukthavaram, R., Tucci, F. C., Ravula, S. B., Lopez, A., Knowles, S., Stein, G. D., Li, Y., Stork, B., Dsouza, R. C. J., Kumar, A., Kittler, R., Tuma, A. C. M., Sarkaria, J. N., Gough, D. J., Stewart, R. A., Kesari, S., Day, B. W., Johns, T. G. ·· 1 day agoPickScore59
Pharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma
In brief
CT-179, a brain-penetrant small-molecule inhibitor of OLIG2, suppressed proliferation in all 11 patient-derived GBM cell lines (IC50 < 360 nM) and induced apoptosis through mitotic catastrophe, mitotic slippage, or a mixed response.
Why it matters
The paper links target engagement, cellular mechanism, and multiple patient-derived orthotopic models to build a preclinical chain from OLIG2 inhibition to extended survival.
Source: bioRxiv